Future studies should include larger, more homogeneous patient populations, carefully account for confounding factors, and incorporate prospective sample size calculations to better define the clinical relevance of SIRT1 as a biomarker in CKD. The gene discussed is SIRT1; the disease is chronic kidney disease.